Order Article Reprints

Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y, et al. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences. 2017; 18(5):906. https://doi.org/10.3390/ijms18050906

Kanda, Tatsuo, Shin Yasui, Masato Nakamura, Eiichiro Suzuki, Makoto Arai, Yoshihiko Ooka, Sadahisa Ogasawara, Tetsuhiro Chiba, Tomoko Saito, Yuki Haga, and et al. 2017. "Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors" International Journal of Molecular Sciences 18, no. 5: 906. https://doi.org/10.3390/ijms18050906

Kanda, T., Yasui, S., Nakamura, M., Suzuki, E., Arai, M., Ooka, Y., Ogasawara, S., Chiba, T., Saito, T., Haga, Y., Takahashi, K., Sasaki, R., Wu, S., Nakamoto, S., Tawada, A., Maruyama, H., Imazeki, F., Kato, N., & Yokosuka, O. (2017). Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences, 18(5), 906. https://doi.org/10.3390/ijms18050906